Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Novavax phase 2 South Africa (2019nCoV-501)
RCTNuvaxovid (NVX-CoV2373) NovavaxplaceboCOVID-19 prophylaxis (excluding children)some concern
2199/2188 suggested
  • suggested 49 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
Novavax PREVEND-19 phase 3 US (2019nCoV-301)
RCTNuvaxovid (NVX-CoV2373) NovavaxplaceboCOVID-19 prophylaxis (excluding children)low
-/- suggested
  • suggested 90 % decrease in confirmed COVID (any severity) with a high degree of certainty due to low risk of bias
2 studies excluded by filtering options (2 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).